Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants are actively enrolled in an Anthem-affiliated commercial, Medicaid, or Medicare health plan with medical and pharmacy benefits.~* Participants must have a smartphone with data plan.~* Participants currently prescribed aripiprazole, or appropriate for aripiprazole treatment.~* Participants must have a current diagnosis of SCH, BP1, or MDD.~Exclusion Criteria:~* Any participant who participated in another clinical trial within 30 days of enrollment into the current study.~* Females who are breast-feeding and/or who are pregnant at the time of study enrollment, or who plan to become pregnant during the study.~* Participants who are currently being treated with a long-acting injectable antipsychotic.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 63 Years
- Healthy Volunteers: f

Study Arms:
- Abilify MyCite (Type: EXPERIMENTAL): Participants received Abilify MyCite during Months 1-3. During Months 4-6 use of Abilify MyCite was to be prohibited. Thereafter, at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) could have been initiated per the joint decision of the participants with their study physician.
- Virtual Matched Controls (Type: ACTIVE_COMPARATOR): Virtual matched controls were to receive treatment as usual (that is, any product other than Abilify MyCite, which could have been oral aripiprazole or any other product) throughout the duration of the trial. Virtual matched controls were not to be enrolled into the study, but identified from health insurance claims data and matched to the enrolled Abilify MyCite participants at the end of the study for analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).